Press Releases News Events Publications Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar’s midphase prospect Lilly ventures into pulmonary fibrosis with startup Mediar Backed by broad syndicate, Mediar takes downstream approach to fibrosis With focus on fibrosis, startup Mediar draws big pharma backing Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift $105M raised: Mediar wins big pharma backing for novel fibrosis therapies Big Pharma companies back new startup out of Mass General Brigham MGB-backed biotech raises $85m to develop drugs for diseases that cause scarring in organs Five pharmas back $85M Series A for Mediar’s fibrosis-modulating antibodies Armed with $105M and Big Pharma backing, Mediar takes aim at fibrotic mediators Mediar Therapeutics Raises $105M in Funding Mediar Therapeutics boosts fibrosis portfolio with $105M financing Mediar Therapeutics Raises $105 Million Financing Mediar raises $105 million to target fibrotic mediators Big Pharma, VCs Bet $105M on Mediar’s Antibodies for Fibrotic Diseases
